medonline
To see this content from Vimeo, you must give your consent to allow cookies from Vimeo to be stored on your device.
Contents in the Video:
00:00
Lack of new phase III trials, but many updates to immunotherapy and targeted therapies
00:50
Keynote-001: lessons to learn from long term survivors
02:47
Keynote-189: strong benefit irrespective of PD-L1
03:54
Biomarker: PD-L1 expression differs in every organ, bone or tissue influencing the predictive outcome
05:45
MYSTIC: bTMB as predictive biomarker for OS with Durvalumab ± Tremelimumab vs chemotherapy
06:32
Targeted therapies for rare entities are numerous in phase I and II and work well with acceptable toxicities
07:45
The new RET-Inhibitors on the block: LOXO-292, BLU-667
08:15
Reponectrinib: the next-generation ROS1/TRK/ALK TKI
08:45
New potent MET Exon 14 inhibitors: tepotinib, catnitinib
09:22
Antitumour activity is also shown for TAK-788 in NSCLC with EGFR exon 20 insertions
09:42
Dual blockade of EGFR and VEGFR pathways for the first line
11:45
JNJ 372: an extremely promising EGFR and cMET blocker
12:38
U3-1402: a treatment option for EGFRm NSCLC resistant to EGFR TKIs
13:20
The combination of bevacizumab and pemetrexed cannot be recommended as maintenance
Interview with:
Prof. Solange Peters, MD, PhD
Interview by:
Dr. Rosalia Rutter
Produced by:
Mag. Oliver Eberhardt
Dr. Rosalia Rutter
Dr. Rosalia Rutter
4 Jun 2019

ASCO 2019 Breakfast Brief – Lung cancer

In this Breakfast Brief Prof. Dr. Solange Peters, Central University Hospital (CHUV) in Lausanne, presents new and noteworthy trials dominating current discussions in lung cancer.